Powered by

MicroVention® And Terumo Corporation Announce Data From Multicenter GREAT Study

 MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced today that the multicenter GREAT study achieved its primary and secondary endpoints.  The primary endpoint of the study was met with statistical significance showing lower adverse composite outcomes in the patients treated with 2nd generation HydroCoil® Embolic System coils when compared to bare platinum coils.

The GREAT study (GermanRandomizedEndovascularAneurysmTrial) was a prospective, randomized, control

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox